ITK 1

Drug Profile

ITK 1

Alternative Names: Personalised peptide vaccine

Latest Information Update: 12 Jul 2017

Price : $50

At a glance

  • Originator Kurume University
  • Developer BrightPath Biotherapeutics; FUJIFILM Corporation; Kurume University
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glioblastoma; Prostate cancer

Most Recent Events

  • 01 Jul 2017 GreenPeptide is now called BrightPath Biotherapeutics
  • 02 Jun 2017 Efficacy and adverse events data from a phase III trial in Glioblastoma multiforme (Monotherapy, Second-line therapy or greater) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 10 Feb 2016 ITK 1 is still in phase III trials for Glioblastoma and Prostate cancer (Second-line therapy or greater) in Japan (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top